A significant driver of top-line growth: Atricure Inc (ATRC)

With 0.54 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.64 million shares. During the session, the Medical Instruments & Supplies company that operates in wider Healthcare sector, reached to the highest price of $30.58 whereas the lowest price it dropped to was $29.61. The 52-week range on ATRC shows that it touched its highest point at $59.61 and its lowest point at $27.92 during that stretch. It currently has a 1-year price target of $54.38. Beta for the stock currently stands at 1.38.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ATRC was up-trending over the past week, with a rise of 2.32%, but this was down by -10.42% over a month. Three-month performance dropped to -18.01% while six-month performance fell -29.16%. The stock lost -25.15% in the past year, while it has lost -14.77% so far this year. A look at the trailing 12-month EPS for ATRC yields -0.66 with Next year EPS estimates of -0.58. For the next quarter, that number is -0.22. This implies an EPS growth rate of -10.42% for this year and 21.01% for next year. EPS is expected to grow by 20.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -1.17%.

Float and Shares Shorts:

At present, 47.53 million ATRC shares are outstanding with a float of 45.95 million shares on hand for trading. On Mar 15, 2024, short shares totaled 2.97 million, which was 6.25% higher than short shares on Feb 15, 2024. In addition to ATRA as the firm’s Atara Biotherapeutics, Inc., AMRC serves as its Ameresco, Inc.

Institutional Ownership:

Through their ownership of 102.25% of ATRC’s outstanding shares, institutional investors have majority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ATRC since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.

Dividends & Yield:

In terms of dividends, ATRC has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and ATRC currently yields $0.00. In the past year, ATRC’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, ATRC has a current buyback yield of $0.45. This was $0.45 for the TTM, and it was $– for the past five years.